Secuenciación en cáncer de mama avanzado HER2+ - page 22

ORR:
79.7%
PERUSE: Global safety study
Bachelot, SABCS2016
1...,12,13,14,15,16,17,18,19,20,21 23,24,25,26,27,28,29,30,31,32,...60
Powered by FlippingBook